Objective: Skin patches that are thick, red, and scaly with a tendency to reoccur over time are the hallmark of the chronic autoimmune illness psoriasis. Cyclosporine and methotrexate have been two widely used therapies for severe psoriasis for a long time. Our goal in this research is to evaluate the clinical efficacy of methotrexate and cyclosporine as treatments for severe psoriasis. We want to learn about their results and provide some insight into how managing this difficult illness could benefit them. Methods: To learn more about the health of patients who were hospitalized because of severe psoriasis during the previous three years, Mayo Hospital in Lahore thoroughly analyzed their medical data. The goal of this research was to evaluate several outcomes connected to the severity of the illness, including the PASI score for the psoriasis area and severity and the length of hospitalization. Results: There were 26 patients in the research study in all. With a standard deviation of 24.64, the average decrease in the PASI (Psoriasis Area Severity Index) was determined to be 42.8%. In comparison to the methotrexate group, which had a lower drop in PASI (mean of 43.22% with a standard deviation of 24.4%) than the cyclosporine group (mean of 54.88% with a standard deviation of 12.73%), researchers found. In addition, the patients in the cyclosporine group received therapy for an average of 18.83 days on average, with a standard deviation of 9.39, as opposed to 11.65 days on average, with a standard deviation of 5.91, in the methotrexate group. Conclusions: Severe psoriasis has been successfully treated with methotrexate and cyclosporine. Patients receiving cyclosporine therapy, however, can have lengthier hospital stays. Keywords: cyclosporine, methotrexate, psoriasis